Accuray Q4 revenue $118.3M (+7.5%); FY GAAP net loss $9.3M vs $5.3M prior year

ACCURAY INC

2023-FY EPS reported -$0.10 revenue$447,605,000

Q4 net revenue $118.3M (+7.5% YoY); GAAP net loss $2.6M ($0.03/share) vs loss $3.5M prior year.
FY2023 net revenue $447.6M (+4.1%); GAAP net loss $9.3M ($0.10/share) vs loss $5.3M prior year.
Adjusted EBITDA Q4 $5.2M (includes $2M bad debt reserve from customer bankruptcy); FY23 $23.9M vs $22.8M prior year.
Gross orders Q4 $88.4M (1.4 book-to-bill); FY23 $311.1M (1.3 book-to-bill); backlog $510.6M.
Issued FY2024 guidance; highlights: 5% installed base growth, positive free cash flow, 510(k) clearance for VitalHold breast package.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ACCURAY INC reported the fourth quarter and fiscal year ended June 30, 2023 results: revenue Net revenue of $118.3 million, net income GAAP net loss of $2.6 million, EPS $0.03 per share.

Period: the fourth quarter and fiscal year ended June 30, 2023
Revenue: Net revenue of $118.3 million
Net income: GAAP net loss of $2.6 million
EPS: $0.03 per share
Result: reported results

Exact text from the filing

Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2023, ended June 30, 2023. Fourth Quarter Fiscal 2023 Summary • Net revenue of $118.3 million, an increase of 7.5 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $120.1 million, which represents a 9.1 percent increase

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

ACCURAY INC filing history →

Source: SEC EDGAR

accession 0000950170-23-040538

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.